If you have CLL and have been treated with either ibrutinib (Imbruvica) or venetoclax (ABT-199) you can help by completing our survey.
Lymphoma Canada is preparing submissions to the panCanadian Oncology Drug Review (pCODR) for:
Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine-based treatment is considered inappropriate
Venetoclax (ABT-199) for patients with relapsed/refractory CLL
You can help by completing our survey, which will provide us with the patient input required for the submissions. pCODR uses this information to help them make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THESE TREATMENTS IN CANADA.
The survey will be open until midnight Pacific Time on Wednesday, April 20th and should only take 10 minutes of your time.
You may access the survey by clicking the link below.